Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development.

@article{Thompson2011RiskAA,
  title={Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development.},
  author={Richard A. Thompson and Emre M Isin and Yan Li and Richard Weaver and Lars Weidolf and Ian Wilson and Alf Claesson and Ken R Page and Hugues Dolgos and John Gerry Kenna},
  journal={Chemico-biological interactions},
  year={2011},
  volume={192 1-2},
  pages={65-71}
}
Drug toxicity is a leading cause of attrition of candidate drugs during drug development as well as of withdrawal of drugs post-licensing due to adverse drug reactions in man. These adverse drug reactions cause a broad range of clinically severe conditions including both highly reproducible and dose dependent toxicities as well as relatively infrequent and idiosyncratic adverse events. The underlying risk factors can be split into two groups: (1) drug-related and (2) patient-related. The drug… CONTINUE READING
30 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Similar Papers

Loading similar papers…